Sam Rebello

About Sam Rebello

My pursuit of science began during doctoral studies at the University of Illinois in unlocking the role of endothelin in cardiovascular regulation. This was fueled by a 3-year industry-sponsored, postdoctoral fellowship at the University of Michigan Medical School. My entrance into the industry was as a Pharmacologist in Rhone-Poulenc Rorer. Here, my team profiled PKPD of Klerval and Otamixaban as antithrombotic agents for Acute Coronary Syndrome. Then, a merger with Hoechst Marion Rousell formed Aventis, offering an opportunity to work in discovery DMPK support for multiple therapeutic areas. This resulted in an exciting 3-year assignment in Aventis France to lead a group of 25 associates in supporting discovery activities from the DMPK perspective. This was not only a professionally-rewarding experience, but also one of cultural enrichment. With the intention of learning more about late-stage development, I moved to Novartis to join the clinical PKPD group. Herein, I led a group of dedicated scientists in supporting projects from Phase 1 and beyond (NDA filings for combo products and Entresto®). I also led a preclinical group in implementing drug interaction and metabolism strategies by demonstrating clinical impact in development projects, and by influencing regulatory strategies. To experiment with biotech, I pursued a non-traditional path toward drug development at Axcella. Here, I built a Development Sciences group (Analytical Chemistry, DMPK, Toxicology and Clinical Pharmacology) to transition lead candidates into successful POC studies. Through the glorious 25+ years of my journey in pharma, from Drug Discovery to Development of diverse therapeutics, I still feel like a student of science, because human biology remains an unsolved mystery. At Eikon, we are leveraging Single Molecule Tracking to better understand the MOA. Won\'t it be nice if we could visualize drug-target interaction in a living cell? Seeing is believing!

Experience

1. VP, Clinical Pharmacology

   Eikon Therapeutics

   Apr 2023 — Present · New York, NY, US

   Group Leader for building Clinical Pharmacology at Eikon to support Oncology/Immunology/CNS therapeutics.

Education

• Bhavans College

  Higher Secondary Certificate (Junior College), Science

  1983 — 1985

• University of Bombay

  Bachelor of Pharmacy (B.Pharm.)

  1985 — 1989

• University of Illinois Chicago

  Doctor of Philosophy (Ph.D.), Pharmacology

  1990 — 1994

• St. Augustine's High School

  Secondary School Certificate

  1973 — 1983

Skills

• Drug Discovery
• Clinical Trials
• U.s. Food and Drug Administration (Fda)
• Biomarker Discovery
• Dmpk
• Pharmaceutical Industry
• Leadership Development
• Metabolism
• Clinical Development
• Clinical Research
• Clinical Pharmacology
• Regulatory Affairs
• Therapeutic Areas
• Pharmacology
• Standard Operating Procedure (Sop)
• Oncology
• Life Sciences
• Regulatory Submissions
• Ind
• Biopharmaceutics
• Drug Development
• Preclinical Pharmacology
• Good Laboratory Practice (Glp)
• Pharmaceutical Sales
• Pharmacokinetics
• Biomarkers